Regeneron Pharmaceuticals Inc

Abierto

SectorSanidad

632.9 2.31

Resumen

Variación precio

24h

Actual

Mínimo

618.17

Máximo

638.5

Métricas clave

By Trading Economics

Ingresos

-117M

727M

Ventas

-279M

3.6B

P/B

Media del Sector

14.946

50.958

BPA

9.47

Rentabilidad por dividendo

0.59

Margen de beneficios

20.17

Empleados

15,343

EBITDA

-234M

967M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+32.64% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

0.59%

2.41%

Próximas Ganancias

30 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-14B

64B

Apertura anterior

630.59

Cierre anterior

632.9

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

51 / 342 Clasificación en Healthcare

Regeneron Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 jun 2026, 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

24 jun 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

23 jun 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

22 jun 2026, 19:56 UTC

Social Media
News

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

18 jun 2026, 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

17 jun 2026, 19:53 UTC

Macro Event

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

16 jun 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

15 jun 2026, 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

13 jun 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

12 jun 2026, 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

11 jun 2026, 23:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, rebounding from earlier fluctuations despite no specific news to explain the movement.

10 jun 2026, 23:11 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, supported by a rise in the Biotechnology sub-sector. The stock remains near its one-month low.

9 jun 2026, 19:56 UTC

News

Regeneron Pharmaceuticals shares are higher following WHO's endorsement of its antibody therapy maftivimab for clinical trials against Bundibugyo ebolavirus.

8 jun 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market dynamics influenced by recent U.S. jobs data.

5 jun 2026, 20:07 UTC

Event

Regeneron Pharmaceuticals shares are higher as Teva launches AHZANTIVE, a biosimilar to Eylea, enhancing its ophthalmology portfolio and impacting Regeneron's competitive position.

4 jun 2026, 19:56 UTC

Social Media
Event
News
Correlated Moves

Regeneron Pharmaceuticals is gaining momentum ahead of presentations at major medical conferences in June, showcasing new clinical data on key therapies.

3 jun 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, following a session peak. No specific news was identified to explain the movement.

2 jun 2026, 23:21 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, driven by gains in the Biotechnology sub-sector, marking a notable change from recent performance.

1 jun 2026, 20:03 UTC

News

Regeneron Pharmaceuticals is under pressure following an investigation announcement by Bronstein, Gewirtz & Grossman, LLC, amid concerns over trial results. Shares are trading lower.

29 may 2026, 20:05 UTC

Social Media
News

Regeneron Pharmaceuticals shares declined following the WHO's recommendation to evaluate maftivimab amid an Ebola outbreak in the Democratic Republic of the Congo and Uganda.

28 may 2026, 23:02 UTC

News
Social Media

Regeneron Pharmaceuticals shares rise after WHO recommends maftivimab for use against the Bundibugyo ebolavirus outbreak in Africa.

27 may 2026, 23:21 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from recent declines but remain below the 20-day moving average. No specific news was identified.

26 may 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, continuing a recent trend of declines amid broader market weakness and no specific news identified.

22 may 2026, 19:37 UTC

Event
News

Regeneron Pharmaceuticals shares are lower today amid investor caution following an investigation into potential claims related to prior trial results.

21 may 2026, 22:51 UTC

News

Regeneron Pharmaceuticals shares rise after positive Phase 1/2 trial results for Lynozyfic®, showing complete response in patients and improved organ function.

20 may 2026, 23:21 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, though they remain below the 20-day moving average and near the lower end of their monthly range.

19 may 2026, 23:31 UTC

Regeneron Pharmaceuticals shares rose in after-market trading, following an early spike during the regular session, despite remaining below the 20-day moving average.

18 may 2026, 23:26 UTC

Social Media

Regeneron Pharmaceuticals is trading higher in after-market hours following a recent setback in a cancer treatment trial, as analysts assess future strategies.

15 may 2026, 22:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid rising yields and increasing crude oil prices.

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

32.64% repunte

Estimación a 12 Meses

Media 826.9 USD  32.64%

Máximo 995 USD

Mínimo 641 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

21 ratings

15

Comprar

6

Mantener

0

Vender

Sentimiento

By Acuity

51 / 342 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.